ChondroFiller Injection Evidence Patients Should WeighInjected collagen scaffold improves focal cartilage defects by 30 IKDC points — exceeding the minimum clinically important difference — sustaining benefit 2–5 years, though only in joints without advanced osteoarthritis; evidence is limited to small cohorts without a large randomised controlled trial.Injected collagen scaffold improves focal cartilage defects by 30 IKDC points — exceeding the minimum clinically important difference — sustaining benefit 2–5 years, though only in joints without advanced osteoarthritis; evidence is limited to small cohorts without a large randomised controlled trial.
ChondroFiller™ durability compared with ArthrosamidChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.ChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.
Who qualifies for ChondroFiller injectionChondroFiller injects a collagen scaffold into focal cartilage lesions—typically grade III–IV defects under 6 cm²—to recruit the patient's progenitor cells for repair rather than replacing tissue artificially.ChondroFiller injects a collagen scaffold into focal cartilage lesions—typically grade III–IV defects under 6 cm²—to recruit the patient's progenitor cells for repair rather than replacing tissue artificially.
Ten-Year Success Rates for OATS MosaicplastyTen-year success rates for OATS mosaicplasty span 72–89% in young, active patients; failure rates drop to 12.5–14% in optimal candidates (under 40, lesion under 3 cm²) but rise to 38–40% in older patients with larger defects.Ten-year success rates for OATS mosaicplasty span 72–89% in young, active patients; failure rates drop to 12.5–14% in optimal candidates (under 40, lesion under 3 cm²) but rise to 38–40% in older patients with larger defects.
Choosing between ACI and MACI for cartilage repairMACI cartilage grafts show 90% fill at two years but decline to 49% by ten years; 73% become fibrocartilage rather than the hyaline cartilage needed for durability.MACI cartilage grafts show 90% fill at two years but decline to 49% by ten years; 73% become fibrocartilage rather than the hyaline cartilage needed for durability.
ChondroFiller injection versus cartilage surgeryChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.ChondroFiller injection achieves 30 IKDC improvement with 3–8% reoperation and 0% complications; microfracture carries 41% reoperation rates with declining long-term outcomes; ACI/MACI matches functional gains but brings 17% complications and 37% reoperation.
What separates ChondroFiller from Liquid CartilageChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.ChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.
MACI recovery and return to sportMACI recovery takes twelve to eighteen months before high-impact sport. Most patients return to some sport, but only one-third reach their pre-injury level — a gap significantly driven by kinesiophobia, which clinical teams can screen and address through sports psychology support.MACI recovery takes twelve to eighteen months before high-impact sport. Most patients return to some sport, but only one-third reach their pre-injury level — a gap significantly driven by kinesiophobia, which clinical teams can screen and address through sports psychology support.
Meniscus tear: which specialist to see and whether surgery is neededThe meniscus's blood supply determines whether a tear can heal: the outer third can regenerate, the inner zone cannot. For degenerative tears, surgery does not improve outcomes and increases osteoarthritis progression; conservative physiotherapy leads to recovery within four to eight weeks.The meniscus's blood supply determines whether a tear can heal: the outer third can regenerate, the inner zone cannot. For degenerative tears, surgery does not improve outcomes and increases osteoarthritis progression; conservative physiotherapy leads to recovery within four to eight weeks.
Single-stage vs two-stage ACI for cartilage repairTraditional two-stage ACI involves two general anaesthetics separated by a four-to-six-week cell culture period; STACI performs both stages in a single theatre session, requiring one general anaesthetic and eliminating the inter-stage gap.Traditional two-stage ACI involves two general anaesthetics separated by a four-to-six-week cell culture period; STACI performs both stages in a single theatre session, requiring one general anaesthetic and eliminating the inter-stage gap.
Who qualifies for ChondroFiller Liquid Cartilage injectionChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.
ChondroFiller injection costs in the UK and EuropeChondroFiller costs £3,000–£8,000 in the UK, scaled by defect size, delivered as an ultrasound-guided outpatient injection with no surgery or anaesthetic.ChondroFiller costs £3,000–£8,000 in the UK, scaled by defect size, delivered as an ultrasound-guided outpatient injection with no surgery or anaesthetic.